Standout Papers

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results 2023 2026 2024149
  1. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (2023)
    Sham Mailankody, Jeffrey Matous et al. Nature Medicine

Immediate Impact

1 from Science/Nature 57 standout
Sub-graph 1 of 23

Citing Papers

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
2025 Standout
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
2025 Standout

Works of Wendy Ying being referenced

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
2023 Standout

Author Peers

Author Last Decade Papers Cites
Wendy Ying 271 143 296 228 26 935
Claus Sværke 106 144 206 54 33 1.1k
Erik Kouba 227 339 183 133 34 1.0k
Jocelyn M. Weiss 242 150 126 47 24 1.0k
J.J.J. Borm 229 104 46 191 26 958
M Forss 53 63 123 311 39 797
Ying Wu 66 193 287 41 38 1.1k
Nuria García de la Torre 72 78 100 386 34 1.1k
Hidenobu Koga 373 267 91 67 38 1.1k
Angeliki Papapanagiotou 238 213 34 358 54 1.0k
Henrik Holmstrøm 237 221 77 106 39 758

All Works

Loading papers...

Rankless by CCL
2026